Requests for Applications
Seed Grants
Description: These grants fund preliminary ALS research that will support funding applications from other sources for larger scale and more impactful research projects.
Funding: Up to $50,000 over 1 year
LOI Deadline (CLOSED): April 9, 2024, 5:00 p.m. US ET
Full Proposal Deadline (by invitation only): June 20, 2024, 5:00 p.m. U.S. ET
The Hoffman ALS Clinical Trial Awards Program
Description: This program supports early- to mid-stage (phase 1 or 2a) interventional clinical trials of novel or repositioned therapeutics for ALS.
Funding: Up to $1,000,000 over 2–3 years
This opportunity has closed.
Milton Safenowitz Postdoctoral Fellowship Program
Description: This program supports the development of early career scientists by funding junior postdoctoral fellows doing research of high scientific merit and relevance to ALS.
Funding: Up to $150,000 over 2 years
This opportunity has closed.
The Lawrence and Isabel Barnett Drug Development Program
Description: This program supports the preclinical development of new or repurposed treatments for ALS.
Funding: Up to $500,000 over 2 years
This opportunity has closed.
Learn About All Our Awards and Programs
Additional Funding Opportunities
Natural History, Clinical Outcome Assessment and Biomarker Studies of Rare Neurodegenerative Diseases (U01 Clinical Trials Optional)
Funding Organization: U.S. Food and Drug Administration
Description: This funding opportunity is intended to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults.
Funding: Application budgets are not limited but should reflect the actual needs of the proposed project, including both direct and indirect costs for up to 4 years of support.
Deadline: May 6, 2024
Clinical Outcomes and Biomarkers Award
Funding Organization: Department of Defense ALS Research Program
Description: This award supports the development and/or validation of clinical outcomes and biomarkers to enrich ALS clinical trials. Projects can be relevant to a specific therapy, class of therapeutics, or specific ALS subtype (such as a particular genetic mutation).
Funding: Maximum allowable funding for the entire 3-year period of performance is $750,000 for direct costs.
LOI Deadline: May 24, 2024, 5:00 p.m. ET
Application Deadline: July 10, 2024, 11:59 p.m. ET
Pilot Clinical Trial Award Program
Funding Organization: Department of Defense ALS Research Program
Description: This program supports phase 1 or small-scale phase 2 trials investigating safety, feasibility, biomarker application, and therapeutic efficacy in relevant patient populations. These trials can evaluate promising drugs, biologics, or devices or be aimed at improving aspects of patient care and ALS symptom management.
Funding: Maximum allowable funding for the entire 4-year period of performance is $2,000,000 for direct costs.
LOI Deadline: May 24, 2024, 5:00 p.m. ET
Application Deadline: July 10, 2024, 11:59 p.m. ET
Therapeutic Development Award Program
Funding Organization: Department of Defense ALS Research Program
Description: This program supports secondary preclinical validation and/or IND-enabling studies of therapeutics for ALS. Applications supported by this award must begin with lead compounds in hand and include proof-of-concept efficacy data in at least one preclinical model system of ALS, including whole animal and cellular model systems.
Funding: Maximum allowable funding for the entire 3-year period of performance is $1,500,000 for direct costs.
LOI Deadline: May 24, 2024, 5:00 p.m. ET
Application Deadline: July 10, 2024, 11:59 p.m. ET
Therapeutic Idea Award Program
Funding Organization: Department of Defense ALS Research Program
Description: This program supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery. The studies supported by this program are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.
Funding: Maximum allowable funding for the entire 2-year period of performance is $600,000 for direct costs.
LOI Deadline: May 24, 2024, 5:00 p.m. ET
Application Deadline: July 10, 2024, 11:59 p.m. ET
Addressing Rare Diseases
Funding Organization: Patient-Centered Outcomes Research Institute (PCORI)
Description: This opportunity seeks to fund high-quality, patient-centered comparative clinical effectiveness research projects focused on rare diseases, like ALS. PCORI is particularly interested in submissions that address approaches to symptom management, timely diagnosis, and improving care delivery for individuals with rare diseases.
Funding: Direct costs up to $12 million for up to 5 years
Open Date: May 7, 2024
Applicant Town Hall: May 14, 2024, 12:00-1:00 p.m. ET (Click here to register.)
LOI Deadline: June 4, 2024, 5:00 p.m. ET
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
Funding Organization: U.S. Food and Drug Administration
Description: This program funds clinical trials evaluating the efficacy and/or safety of existing products in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions, such as ALS.
Funding: Up to $650,000 per year for 4 years
Open Date: August 23, 2024
Want to add your funding opportunity to this list? Contact us at ResearchGrants@als.org.
